Lyell Immunopharma, Inc. Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount
Lyell Immunopharma, Inc. (LYEL) reported Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount of 49.44 million shares for the 6-month period ending 2022-06-30, per its 10-Q filed 2022-08-04.
Discontinued › Income Statement › Earnings Per Share
us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount · last filed 2022-08-04
- Lyell Immunopharma, Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2022-03-31 was 50.63M shares, a 78.95% decline year-over-year.
- Lyell Immunopharma, Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2021-09-30 was 47.14M shares, a 80.05% decline year-over-year.
- Lyell Immunopharma, Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2021-06-30 was 46.73M shares, a 80.30% decline year-over-year.
- Lyell Immunopharma, Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2021-03-31 was 240.56M shares.
- Lyell Immunopharma, Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2021 was 44.38M shares, a 81.23% decline from fiscal 2020.
- Lyell Immunopharma, Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2020 was 236.45M shares, a 22.64% increase from fiscal 2019.
- Lyell Immunopharma, Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2019 was 192.81M shares.
| Period end | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 3 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 6 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 9 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 12 month |
|---|---|---|---|---|
| 2022-06-30 | 49.44M shares 10-Q · filed 2022-08-04 | |||
| 2022-03-31 | 50.63M shares 10-Q · filed 2022-05-10 | |||
| 2021-12-31 | 44.38M shares 10-K · filed 2022-03-29 | |||
| 2021-09-30 | 47.14M shares 10-Q · filed 2021-11-12 | 47.14M shares 10-Q · filed 2021-11-12 | ||
| 2021-06-30 | 46.73M shares 10-Q · filed 2021-08-12 | 46.73M shares 10-Q · filed 2022-08-04 | ||
| 2021-03-31 | 240.56M shares 10-Q · filed 2022-05-10 | |||
| 2020-12-31 | 236.45M shares 10-K · filed 2022-03-29 | |||
| 2020-09-30 | 236.32M shares 10-Q · filed 2021-11-12 | 236.32M shares 10-Q · filed 2021-11-12 | ||
| 2020-06-30 | 237.21M shares 10-Q · filed 2021-08-12 | 237.21M shares 10-Q · filed 2021-08-12 | ||
| 2019-12-31 | 192.81M shares 10-K · filed 2022-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |